Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Alpha Cognition Inc ACOG

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.


NDAQ:ACOG - Post by User

Post by stockpatrolon Dec 30, 2021 4:33pm
143 Views
Post# 34272142

$ACOG.v / $ACOGF

$ACOG.v / $ACOGF

$ACOG.v / $ACOGF is a biopharmaceutical company currently in clinical trial for their ALPHA-1062, treating under-served neurodegenerative diseases. 

 

https://www.youtube.com/watch?v=-QQSJNvmUuc&ab_channel=RadiusResearch 

 

Here’s a great video to get acquainted with $ACOG.v they’ve been getting a lot of good press recently and for good reason. 

 

APLHA-1062 potentially proving to be the best in its class with patients 45% of whom cannot have acetylcholinesterase inhibitor (AChEI) drugs due to stomach problems.  

 

“Alpha Cognition is de-risked, late stage, and offers a unique combination of high reward with less-than-usual risk thanks to the well-established AChEI market and our evaluation of its preclinical and clinical data in the context of a 505(b)(2) pathway to approval,” Stellick wrote. 

 

https://www.cantechletter.com/2021/12/three-canadian-biopharma-stocks-for-2022/# 

<< Previous
Bullboard Posts
Next >>